

1 **Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta**
2 **variant in a federal prison, July—August 2021**

3 Phillip P. Salvatore, PhD, SM – CDC COVID-19 Response Team
4 Christine C. Lee, PhD – CDC COVID-19 Response Team; Laboratory Leadership Service
5 Sadia Sleweon, MPH – CDC COVID-19 Response Team
6 David W. McCormick, MD, MPH – CDC COVID-19 Response Team; Epidemic Intelligence Service
7 Lavinia Nicolae, PhD – CDC COVID-19 Response Team
8 Kristen Knipe – CDC COVID-19 Response Team
9 Thomas Dixon – Bureau of Prisons, U.S. Department of Justice
10 Robert Banta, MSN – Bureau of Prisons, U.S. Department of Justice
11 Isaac Ogle, MSN – Bureau of Prisons, U.S. Department of Justice
12 Cristen Young – Bureau of Prisons, U.S. Department of Justice
13 Charles Dusseau – Bureau of Prisons, U.S. Department of Justice
14 Shawn Salmonson – Bureau of Prisons, U.S. Department of Justice
15 Charles Ogden, MPH – Bureau of Prisons, U.S. Department of Justice
16 Eric Godwin – Bureau of Prisons, U.S. Department of Justice
17 TeCora Ballom, DO – Bureau of Prisons, U.S. Department of Justice
18 Tara Ross – Bureau of Prisons, U.S. Department of Justice
19 Nhien Tran Wynn, MS – CDC COVID-19 Response Team
20 Ebenezer David, PhD – CDC COVID-19 Response Team
21 Theresa K. Bessey, PhD – CDC COVID-19 Response Team
22 Gimin Kim – CDC COVID-19 Response Team
23 Suganthi Suppiah, PhD – CDC COVID-19 Response Team
24 Azaibi Tamin, PhD – CDC COVID-19 Response Team
25 Jennifer L. Harcourt, PhD – CDC COVID-19 Response Team
26 Mili Sheth – CDC COVID-19 Response Team
27 Luis Lowe, MS, MPH – CDC COVID-19 Response Team
28 Hannah Browne – CDC COVID-19 Response Team
29 Jacqueline E. Tate, PhD – CDC COVID-19 Response Team
30 Hannah L. Kirking, MD – CDC COVID-19 Response Team
31 Liesl M. Hagan, MPH – CDC COVID-19 Response Team

32
33 **Disclaimer.** The findings and conclusions in this report are those of the author(s) and do not necessarily
34 represent the official position of Centers for Disease Control and Prevention (CDC).

35

36 **Abstract**

37 *Background*

38 The extent to which vaccinated persons who become infected with SARS-CoV-2 contribute to
39 transmission is unclear. During a SARS-CoV-2 Delta variant outbreak among incarcerated persons with
40 high vaccination rates in a federal prison, we assessed markers of viral shedding in vaccinated and
41 unvaccinated persons.

42 *Methods*

43 Consenting incarcerated persons with confirmed SARS-CoV-2 infection provided mid-turbinate
44 nasal specimens daily for 10 consecutive days and reported symptom data via questionnaire. Real-time
45 reverse transcription-polymerase chain reaction (RT-PCR), viral whole genome sequencing, and viral
46 culture was performed on these nasal specimens. Duration of RT-PCR positivity and viral culture
47 positivity was assessed using survival analysis.

48 *Results*

49 A total of 978 specimens were provided by 95 participants, of whom 78 (82%) were fully
50 vaccinated and 17 (18%) were not fully vaccinated. No significant differences were detected in duration
51 of RT-PCR positivity among fully vaccinated participants (median: 13 days) versus those not fully
52 vaccinated (median: 13 days; $p=0.50$), or in duration of culture positivity (medians: 5 days and 5 days;
53 $p=0.29$). Among fully vaccinated participants, overall duration of culture positivity was shorter among
54 Moderna vaccine recipients versus Pfizer ($p=0.048$) or Janssen ($p=0.003$) vaccine recipients.

55 *Conclusions*

56 As this field continues to develop, clinicians and public health practitioners should consider vaccinated
57 persons who become infected with SARS-CoV-2 to be no less infectious than unvaccinated persons.
58 These findings are critically important, especially in congregate settings where viral transmission can
59 lead to large outbreaks.

60 **Introduction**

61 COVID-19 vaccines are highly effective in preventing severe illness and death from SARS-CoV-2
62 (the virus that causes COVID-19). However, because COVID-19 vaccines are not 100% effective in
63 preventing infection, some infections among vaccinated persons are expected to occur. As global
64 vaccination coverage increases, the role of vaccinated persons in transmission will be a critical
65 determinant of the pandemic's future trajectory.¹ The extent to which vaccinated persons who become
66 infected contribute to transmission of SARS-CoV-2, including the B.1.617.2 (Delta) variant, is not yet well
67 understood. Some preprint manuscripts have reported comparable indicators of transmission potential
68 regardless of vaccination status,² while others have reported reduced viability of virus isolated from
69 vaccinated persons.³

70 The Delta variant has been associated with a peak in COVID-19 cases in the United States
71 beginning in July 2021 that included large outbreaks among vaccinated and unvaccinated persons in
72 crowded settings.⁴⁻⁶ These findings are of particular concern for congregate living environments such as
73 correctional and detention facilities and long-term care facilities because of the potential for rapid
74 transmission of SARS-CoV-2 and the high prevalence of underlying health conditions associated with
75 severe COVID-19.⁷⁻⁹

76 In a recent outbreak involving the Delta variant in a federal prison in Texas, the cumulative
77 incidence of infection in two affected housing units was 74%; it was 93% and 70% among unvaccinated
78 and vaccinated incarcerated persons, respectively.⁶ Using serial mid-turbinate nasal specimens collected
79 from a subset of incarcerated persons infected during this outbreak, this report assesses reverse
80 transcription-polymerase chain reaction (RT-PCR) and viral culture characteristics as surrogate markers
81 of transmission potential among persons fully vaccinated and those not fully vaccinated over time. This
82 report is one of the first longitudinal investigations of viral shedding from vaccinated persons infected

83 with the Delta variant and contributes to the evidence base guiding infection prevention and control
84 procedures across a variety of settings.

85

86 **Methods**

87 *Investigational Setting*

88 On July 12, 2021, an outbreak of SARS-CoV-2 among vaccinated and unvaccinated persons was
89 detected in a federal prison in Texas. Staff from the Centers for Disease Control and Prevention (CDC)
90 and Federal Bureau of Prisons (BOP) deployed to the prison to investigate the outbreak as previously
91 reported.⁶ As part of this outbreak investigation, a subset of incarcerated persons provided serial mid
92 turbinate nasal specimens which were analyzed to evaluate the potential role of infected vaccinated and
93 unvaccinated persons in transmission of SARS-CoV-2. This activity was reviewed and approved by the
94 BOP Research Review Board and CDC and conducted consistent with applicable federal law and CDC
95 policy.*

96

97 *Participant Enrollment and Serial Specimen Collection*

98 Incarcerated persons living in four housing units where COVID-19 cases had been identified
99 were invited to participate in serial swabbing. Persons were eligible to enroll if they had tested positive
100 for SARS-CoV-2 between July 12 (the start of the outbreak) and August 4, 2021. CDC and BOP staff held
101 information sessions to explain the purpose of the project and to answer questions, including privacy
102 protections and how results of the study would be made available to participants. All persons choosing
103 to participate signed informed consent forms, which were provided in English and Spanish.

104 Specimen collection occurred during July 18—August 9, 2021. CDC and BOP staff collected one
105 nasal mid-turbinate specimen daily for 10 consecutive days from participants who had tested positive,

106 beginning on July 19 or, for cases identified after July 19, beginning on the date of participants' first
107 positive test. All incarcerated persons residing in housing units where cases were identified were placed
108 under quarantine precautions. To assist in case-finding, consenting persons who were quarantined were
109 tested every other day beginning on July 19 or on their first full day of quarantine; those who tested
110 positive during quarantine were invited to participate in the 10 consecutive days of specimen collection.
111 All participants were asked to provide a specimen on August 6 to provide data additional data on viral
112 shedding, which corresponds to a late timepoint in infection for most participants (Figure 1).

113 On the tenth day of specimen collection, participants were asked to complete a paper-based
114 questionnaire to report COVID-19-like symptoms during the course of their illness, including date of
115 symptom onset and symptom duration. Information on demographic characteristics, COVID-19
116 vaccination history, previous positive SARS-CoV-2 diagnostic tests, and underlying medical conditions
117 was extracted from BOP electronic medical records for all participants.

118

119 *Laboratory Methods*

120 Specimens were collected using nylon flocked minitip swabs, transferred into
121 universal viral transport media (VTM) (Becton Dickinson, Franklin Lakes, NJ) immediately stored at 2-8°C
122 and frozen at -20°C or colder within 72 hours, and sent to CDC for RT-PCR testing using the CDC
123 Influenza SARS-CoV-2 Multiplex Assay. Remnant aliquots were stored at -70°C or below for viral culture.
124 Due to capacity limitations, viral culture was performed on a subset of collected specimens. Specimens
125 were included for viral culture if they had been collected 0, 3, 5, 7, or 9 days since onset and had an
126 accompanying positive RT-PCR test with cycle threshold (Ct) value less than 35. For verification that this
127 selected Ct cutoff did not exclude specimens containing culturable virus, viral culture was also
128 performed on 25 of 102 specimens with Ct>35. (25/25 of these specimens were culture negative.) For
129 more granular detail across the time-course of infection, viral culture was also performed on a subset of

130 specimens collected on other days (see Supplemental Figures 1-2 for details on specimens included for
131 viral culture).

132 Specimens selected for culture were used to perform limiting-diluting inoculation of Vero CCL-
133 81 cells expressing TMPRSS2, and cultures showing evidence of cytopathic effect were tested by RT-PCR
134 for the presence of SARS-CoV-2 RNA. Viral recovery was as previously described.¹⁰ Whole genome
135 sequencing (WGS) was performed for one RT-PCR-positive specimen per participant with Ct less than 30
136 (per sequencing laboratory standard protocols).

137

138 *Statistical Methods*

139 Onset (used as time 0 in longitudinal analyses below) was defined to be either a) date of first
140 onset of self-reported symptom(s) meeting the case definition of COVID-19,¹¹ or b) date of first positive
141 diagnostic SARS-CoV-2 test, whichever occurred first. In two instances where a participant without
142 symptoms had an initial positive test followed by at least 3 negative tests before subsequent positive
143 tests, the date of second positive test was used.

144 Participants were considered fully vaccinated if ≥ 14 days had elapsed since they had completed
145 all recommended doses of a COVID-19 primary vaccine series before the start of the outbreak. (No
146 participant had completed a primary vaccine series < 14 days before the outbreak.) Participants were
147 considered not fully vaccinated if they had not received any doses of a vaccine or if they had not
148 completed all doses of a vaccine series. Demographic characteristics of participants stratified by
149 vaccination status were assessed using Fisher's exact tests.

150 Three surrogate markers for assessing transmission potential were analyzed as primary
151 outcomes: RT-PCR positivity (an indicator of current/recent infection), RT-PCR Ct value (a semi-
152 quantitative indicator of relative level of viral nucleic acid), and viral culture positivity (an indicator of
153 viable/infectious virus). Dichotomous laboratory results (RT-PCR positivity and viral culture positivity)

154 were analyzed longitudinally with time 0 defined as the date of onset and the primary endpoints defined
155 by a participant's last positive test. Specimens for which viral culture was not performed were presumed
156 to be culture negative if an accompanying RT-PCR test was negative or was positive with Ct>35. To
157 account for variation in the interval between onset and enrollment, and intermittent participation in
158 specimen collection by some participants (which can result in interval and right censoring), survival
159 analyses were performed using Turnbull estimation using the "interval" package implementation in R.¹²
160 Hypothesis testing of survival functions was performed using the generalized Wilcoxon-Mann-Whitney
161 method for interval-censored data.

162 As a post-hoc evaluation of potential interactions between vaccination status and known prior
163 SARS-CoV-2 infections, a stratified analysis was conducted using Fisher's exact test to compare RT-PCR
164 and viral culture results across these two variables among specimens collected on days with complete
165 viral culture coverage (0, 3, 5, 7, and 9 days since onset).

166 Non-dichotomous laboratory results (RT-PCR Ct values) were characterized by days since onset
167 using medians and interquartile ranges (IQRs). Because Ct values are semi-parametric, distributions
168 were compared non-parametrically using the Mann-Whitney U test with ties (for dichotomous variables)
169 or the Kruskal-Wallis test (for categorical variables with more than 2 levels); negative RT-PCR results
170 were assigned higher ranks than any Ct value from positive RT-PCR results. To account for multiple
171 hypothesis testing across days, α thresholds were adjusted using Bonferroni correction. All hypothesis
172 tests performed are detailed in Supplementary Tables 1 and 2. All statistical analyses were performed in
173 R version 4.0.2 (R Core Team, Vienna, Austria).

174

175 **Results**

176 *Population Characteristics*

177 Among 189 persons with SARS-CoV-2 infection eligible to enroll, a total of 96 persons consented
178 to participate in serial specimen collection; one participant had a single positive diagnostic test (Ct=36.2)
179 followed by seven negative diagnostic tests and reported no symptoms and was excluded as a non-case.
180 Of the 95 included participants, 78 (82%) were documented as being fully vaccinated against SARS-CoV-
181 2, 15 (16%) were unvaccinated and 2 (2%) were partially vaccinated and categorized as not fully
182 vaccinated in further analyses (Table 1). Among fully vaccinated participants, a majority (57/78, 73%)
183 received the Pfizer vaccine; smaller proportions received the Moderna vaccine (14/78, 18%) or Janssen
184 vaccine (7/78, 9%). A majority (47/78, 60%) of fully vaccinated participants completed their vaccination
185 series more than 120 days prior to the start of the outbreak (IQR: 81-140 days prior to start). Recipients
186 of Pfizer vaccines completed their series earlier (IQR: 131-131 days) than recipients of Moderna (IQR:
187 81-82 days prior to start) or Janssen (IQR: 46-70 days prior to start) vaccines ($p<0.001$). A small number
188 of participants (2/78 fully vaccinated, 3%, and 2/17 not fully vaccinated, 12%, $p=0.10$) had a documented
189 prior SARS-CoV-2 infection. Based on symptom self-report at the end of sampling, 76% of participants
190 reported at least one symptom in the COVID-19 case definition [CSTE 2021]. The most commonly
191 reported symptoms were runny or stuffy nose (58%), loss of smell or taste (54%), and cough (45%). Of
192 95 specimens from 95 participants for which sequencing was attempted, 64 were successfully
193 sequenced and passed quality metrics; all 64 (100%) belonged to the B.1.617.2 (Delta) lineage and AY.3
194 sublineage.

195

196 *RT-PCR Positivity*

197 From the 95 included participants, 978 specimens were collected for RT-PCR testing (825/978,
198 84% from fully vaccinated participants). Specimens were collected ranging from 13 days prior to onset
199 (among participants tested during quarantine prior to diagnosis) to 32 days following onset. See Figure 1
200 for a diagrammatic representation of RT-PCR specimen collection from participants, and see

201 Supplemental Figure 1 for details of specimen collection by day since onset (stratified by vaccination
202 status). A median of 6 days elapsed between onset and enrollment among fully vaccinated participants,
203 compared with a median of 7 days among participants who were not fully vaccinated ($p=0.33$). Overall,
204 499 of the 978 (51%) specimens tested positive by RT-PCR.

205 No significant differences in time to last RT-PCR positive test were found. Median duration of
206 RT-PCR positivity was 13 days among fully vaccinated participants versus 13 days among participants
207 who were not fully vaccinated ($p=0.50$; Figure 2); and 10 days among participants with known history of
208 prior SARS-CoV-2 infection (regardless of vaccination) versus 13 days among participants without any
209 known prior infection ($p=0.12$). Among fully vaccinated participants, median duration of positivity was
210 10 days among Moderna vaccine recipients versus 13 days among Pfizer recipients and 13 days among
211 Janssen recipients ($p=0.39$); and 13 days among participants fully vaccinated more than 120 days prior
212 to the outbreak versus 11 days among participants vaccinated 120 days or less prior to the outbreak
213 ($p=0.32$).

214

215 *Ct Values*

216 Ct values from specimens testing positive by RT-PCR increased with the number of days since
217 onset (Figure 3). Among specimens from fully vaccinated participants, Ct values increased from a
218 median of 26.4 (IQR: 23.5-28.4) on the day of onset to a median of 32.9 on day 10 (IQR: 30.5-34.6), while
219 Ct values from specimens from participants who were not fully vaccinated increased from a median of
220 28.5 (IQR:24.8-31.8) on the day of onset to a median of 34.5 on day 10 (IQR: 29.4-35.2). Across the time-
221 course of infection, no statistically significant difference was observed among Ct values by vaccination
222 status on any day after Bonferroni correction (all $p>0.0026$, the Bonferroni-corrected α threshold).
223 Additionally, no significant differences were observed among Ct values when stratified by vaccine
224 product, time since vaccination, or known prior SARS-CoV-2 infection. While not statistically significant,

225 lower Ct values were observed early in the time-course of infection among Janssen vaccine recipients
226 (day 3 median: 17.9; IQR: 17.6-19.4) than among Moderna (day 3 median: 27.4; IQR: 23.7-28.1) or Pfizer
227 recipients (day 3 median: 24.8; IQR: 23.1-26.8; $p=0.016$ while Bonferroni $\alpha=0.0026$).

228

229 *Viral Culture Positivity*

230 Of the 978 specimens collected, viral culture was performed on 286 (29%); an additional 556
231 (57%) were included as presumptive negative viral culture results due to an accompanying negative RT-
232 PCR test ($n=479$) or a positive RT-PCR test with a Ct value greater than 35 ($n=77$). Viral culture capture
233 by day since onset stratified by vaccination status is detailed in Supplementary Figure 2. Among the 842
234 specimens with a viral culture result, 75 (9%) had a positive viral culture. Virus was recovered from
235 57/690 (8%) of specimens from fully vaccinated participants, compared with 18/152 (12%) of specimens
236 from participants who were not fully vaccinated ($p=0.16$).

237 No statistically significant difference was detected in the duration of viral culture positivity
238 (Figure 4) between participants who were fully vaccinated (median: 5 days) compared with those who
239 were not fully vaccinated (median: 5 days; $p=0.29$). (Viral culture results are illustrated as a function of
240 days since onset and grouped by RT-PCR result in Supplementary Figure 4). Cumulative hazard functions
241 indicate overall shorter culture positivity for fully vaccinated participants who received the Moderna
242 vaccine than those who received Pfizer ($p=0.048$) or Janssen vaccines ($p=0.003$), but there was no
243 significant difference between recipients of Pfizer and Janssen vaccines ($p=0.12$). No statistically
244 significant differences in duration of culture positivity were detected when stratified according to time
245 since vaccination ($p=0.79$) or known prior infection ($p=0.99$).

246

247 *Factorial Stratification: Vaccination Status and History of Prior Infection*

248 Figure 5 illustrates a post-hoc stratification of RT-PCR and viral culture results by vaccination
249 status and prior SARS-CoV-2 infection. No statistically significant difference in RT-PCR or viral culture
250 positivity was detected on any day; however, bivariate stratification resulted in small population sizes in
251 some groups (n=2 participants each for those fully vaccinated with a known prior infection and those
252 not fully vaccinated with a known prior infection), which limits the ability to draw conclusions about
253 these groups.

254

255 Discussion

256 During a high-transmission outbreak of the SARS-CoV-2 Delta variant in a prison setting, we
257 failed to find different durations of RT-PCR positivity, Ct values, or durations of viral culture positivity in
258 fully vaccinated persons compared with persons who were not fully vaccinated. However, vaccinated
259 persons who received the Moderna vaccine had a shorter duration of culture positivity compared with
260 Pfizer or Janssen vaccine recipients. (However, Moderna vaccine recipients also were more recently
261 vaccinated than Pfizer vaccine recipients.) Collectively, our findings suggest that, as evidence continues
262 to emerge in this developing field, vaccinated persons who become infected should be regarded as not
263 significantly less infectious than unvaccinated persons for the purposes of public health action.

264 As viral infections in vaccinated persons can result from either a failure to mount a protective
265 immune response following initial vaccination or a gradual waning of immunological protection
266 following initially robust protection, the infectiousness of vaccinated persons may be variable. It is
267 plausible that some participants in this investigation who became infected despite vaccination had weak
268 or waning vaccine-induced protection and were therefore similar to unvaccinated persons in the
269 markers of transmission potential that we evaluated.

270 This report adds to a limited body of scientific literature evaluating the transmission potential of
271 SARS-CoV-2 infections in vaccinated persons. Reports of infections in vaccinated persons have found
272 mixed results using markers of transmission potential, and no longitudinal studies of viral culture
273 characteristics in vaccinated persons with Delta infections have been published. A multi-site serial
274 testing investigation involving Alpha (B.1.1.7) and Gamma (P.1) infections found that duration of culture
275 positivity was shorter among vaccinated persons compared with unvaccinated persons.^{13, 14} One report
276 using surveillance data found lower Ct values among unvaccinated persons, but this difference was only
277 observed for two of three RT-PCR probes and only during one of three months.¹⁵ One cross-sectional
278 report found no difference in Ct value by vaccination status.² However, extrapolating from cross-
279 sectional and surveillance data may be challenging without data to account for timing of specimen
280 collection in the course of infection. Nevertheless, this finding is corroborated by analysis of a clinical
281 convenience sample which found vaccination did not impact Ct values and reduced viral recovery of
282 Alpha variant but did not reduce recovery of Delta variant virus;¹⁶ similar findings were mirrored by two
283 retrospective health-system cohorts.^{17, 18} A report of health system workers found that viral culture
284 positivity was reduced in vaccinated persons despite similar Ct values as those in unvaccinated persons.³
285 A separate report found that early in the clinical course of infection, Ct values were comparable
286 between vaccinated and unvaccinated persons, but among individuals who presented to care later in
287 their course of illness, Ct values were higher in vaccinated persons.¹⁹ A study of household transmission
288 of Delta infections found similar peak viral loads regardless of vaccination status, but noted faster
289 declines in vaccinated persons.²⁰ Cumulatively, available data have not clearly or consistently identified
290 markers of reduced transmission potential in vaccinated persons with SARS-CoV-2 infection. This report,
291 which to our awareness represents the first longitudinal investigation of viral culture characteristics of
292 vaccinated persons with Delta variant infections, further demonstrates the potential of vaccinated
293 persons to contribute to SARS-CoV-2 transmission.

294 While our investigation did not find evidence of reduced transmission potential from vaccinated
295 persons with infection, vaccination is known to reduce the risk of infection,^{6, 21} which prevents
296 secondary transmission. In addition, vaccination remains a strongly protective factor against morbidity
297 and mortality due to SARS-CoV-2.²² Protection against infection, morbidity, and mortality underscores
298 the importance of maximizing vaccination coverage, particularly in settings where challenges to physical
299 distancing can result in rapid, widespread transmission when infections do occur.

300 The evidence that vaccinated persons can transmit SARS-CoV-2 to others suggests that there is
301 continued risk of widespread outbreaks when the virus is introduced into congregate settings, even
302 when vaccination coverage is high. In particular, because of the potential for rapid transmission and high
303 prevalence of underlying health conditions in incarcerated populations,^{7, 8} persons living or working in
304 correctional facilities should quarantine after exposure to SARS-CoV-2, regardless of vaccination status.
305 Post-exposure quarantine is especially important where the risk of transmission is high (e.g., in dorm-
306 style housing, and where staff and/or incarcerated persons frequently interact across housing units) or
307 where the population is at high risk of severe outcomes from COVID-19. Facilities can continue to
308 minimize the need for quarantine by enforcing consistent indoor masking to the extent possible,
309 continuing recommended disinfection, cleaning, and ventilation, and maintaining routine test-based
310 screening programs that can identify cases early and facilitate timely action (including isolation) to limit
311 exposure to others. Facilities that implement routine test-based screening should continue to include
312 vaccinated persons in their frame.

313 This report is subject to several limitations. Due to the small proportion of participants who
314 were not fully vaccinated (19%), statistical comparisons on the basis of vaccination status were
315 underpowered, and negative findings reported here warrant cautious interpretation. To increase the
316 sample size of this group, two partially vaccinated participants were included, potentially diluting the
317 characteristics of unvaccinated participants. However, our conclusions did not change when analyses

318 were performed excluding these two participants. Similarly, only four participants had known prior
319 infection, of which a higher proportion occurred in those not fully vaccinated; therefore, these
320 participants may appear to have slightly greater immunological protection than those without prior
321 infection. On average, unvaccinated participants enrolled earlier in the outbreak and later in their
322 course of infection than vaccinated participants; we utilized Turnbull estimation in survival analyses to
323 account for the possibility of interval censoring in this population. All symptom data was self-reported
324 and collected at the end of the specimen collection period, which may have impacted the accuracy of
325 participants' recall related to the date of symptom onset. Ct values are semi-quantitative indicators of
326 viral RNA levels and cannot be interpreted as quantitative markers of viral load or infectiousness. To
327 avoid drawing quantitative conclusions around Ct values, we conservatively utilized non-parametric
328 rank-based statistics (Mann-Whitney and Kruskal-Wallis) with Bonferroni correction to describe Ct
329 values in this investigation. Information on prior SARS-CoV-2 infection was obtained from medical
330 records; persons with earlier infections that were undiagnosed or diagnosed prior to incarceration and
331 not documented in the BOP medical system may not have been correctly characterized. Finally, we did
332 not attempt viral culture for 561 specimens with Ct>35 and classified them as presumptively negative.
333 This decision was based on negative viral culture results from 25/25 specimens with Ct>35 for which
334 viral culture was performed during this investigation, as well as previously published findings
335 demonstrating an inability to recover viable virus from specimens that were RT-PCR negative.²³

336 In this investigation, we found no statistically significant difference in transmission potential
337 between vaccinated persons and persons who were not fully vaccinated. Therefore, our findings
338 indicate that prevention and mitigation measures should be applied without regard to vaccination status
339 for persons in high-risk settings or those with significant exposures. In congregate settings, and
340 correctional and detention facilities in particular, post-exposure testing and quarantine remain essential
341 tools to limit transmission when cases are identified, in addition to other recommended prevention

342 measures.²⁴ Our data add to a growing body of evidence characterizing transmission potential from
343 vaccinated persons. Future studies of transmission potential from vaccinated persons with infection,
344 incorporating similar laboratory-based markers as well as evidence of transmission from secondary
345 attack rates and network analysis, may help to further describe the contributions of vaccinated persons
346 in chains of transmission as the pandemic evolves and new variants emerge.

347 **Conflict of Interest Statement**

348 The authors have no conflicts of interest to report. All authors have completed the ICMJE Conflict of
349 Interest declaration.

350

351 **Acknowledgements**

352 Mario Cordova, Torrey Haskins, Jennifer Jackson, Joshua Jett, Barbara Swopes, Tammy Winbush, Federal
353 Bureau of Prisons.

354

355 **Footnotes**

356 * 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et
357 seq.

358

359 **Table 1. Characteristics of enrolled participants who tested positive for SARS-CoV-2, Federal prison,**
 360 **Texas, July 12—August 9, 2021**

	All participants		Fully vaccinated		Not fully vaccinated*		p-value†
	n	%	n	%	n	%	
Total	95	100%	78	81%	17	19%	
Sex							
Male	95	100%	78	100%	17	100%	
Age							0.4
18-29	5	5%	3	4%	2	12%	
30-39	22	23%	19	24%	3	18%	
40-49	28	29%	22	28%	6	35%	
50-59	25	26%	20	26%	5	29%	
≥ 60	15	16%	14	18%	1	6%	
Race/Ethnicity							0.008
American Indian/Alaska Native	2	2%	2	3%	0	0%	
Asian	1	1%	1	1%	0	0%	
Black	16	17%	8	10%	8	47%	
Hispanic	12	13%	10	13%	2	12%	
White	64	67%	57	73%	7	41%	
Country of birth							0.6
Non US-born	4	4%	3	4%	1	6%	
US-born	91	96%	75	96%	16	94%	
Vaccination status							
Fully vaccinated	78	82%	78	100%	0	0%	
Not fully vaccinated*	17	18%	0	0%	17	100%	
<i>Partially vaccinated</i>	2	2%	0	0%	2	12%	
<i>Unvaccinated</i>	15	16%	0	0%	15	88%	
Vaccine product received							
Janssen	7	7%	7	9%	0	0%	
Moderna	14	15%	14	17%	0	0%	
Pfizer	57	60%	57	74%	0	0%	
Time from full vaccination to outbreak (if fully vaccinated)							
≤120 days	31	33%	31	33%	0	0%	
>120 days	47	49%	47	61%	0	0%	
Medical comorbidities							
Overweight‡	31	33%	24	31%	7	41%	0.3
Obesity‡	47	49%	42	54%	5	29%	
Severe obesity ‡	7	7%	6	8%	1	6%	
History of smoking	46	48%	42	54%	4	24%	0.03
Hypertension	43	45%	38	49%	5	29%	0.1

Diabetes	15	16%	14	18%	1	6%	0.3
Moderate/severe asthma	10	11%	8	10%	2	12%	1.0
Chronic obstructive pulmonary disease	6	6%	6	8%	0	0%	0.6
Cancer	1	1%	1	1%	0	0%	1.0
Chronic kidney disease	2	2%	2	3%	0	0%	1.0
Immunocompromised state	2	2%	2	3%	0	0%	1.0
HIV	0	0%	0	0%	0	0%	
Serious cardiac conditions	0	0%	0	0%	0	0%	
Liver disease	0	0%	0	0%	0	0%	
Documented prior SARS-CoV-2 infection							0.1
No	91	96%	76	97%	15	88%	
Yes	4	4%	2	3%	2	12%	
COVID-19 disease outcomes							
Hospitalization	2	2%	1	1%	1	6%	
Death	0	0%	0	0%	0	0%	
Reported Symptoms							
Reported any symptoms in CSTE case definition§	66	70%	54	70%	12	71%	0.7
Reported any symptoms	72	76%	59	76%	13	76%	0.4
Runny/Stuffy Nose	55	58%	48	62%	7	41%	0.4
Loss of Smell or Taste	51	54%	43	55%	8	44%	1.0
Cough	43	45%	35	45%	8	47%	0.8
Headache	40	42%	33	42%	7	41%	1.0
Muscle Aches	40	42%	30	38%	10	59%	0.08
Subjective Fever	34	36%	27	35%	7	41%	0.6
Measured Fever	10	11%	6	8%	4	24%	0.06
Chills	29	31%	21	27%	8	47%	0.06
Sore Throat	24	25%	21	27%	3	18%	0.7
Shortness of Breath	20	21%	14	18%	6	35%	0.08
Abdominal Pain, Nausea, Vomiting	17	18%	12	15%	5	28%	0.2
Diarrhea	16	17%	11	14%	5	28%	0.1
Other	6	6%	6	8%	0	0%	1.0
None Reported ¶	23	24%	19	24%	4	24%	1.0

361 *Not fully vaccinated participants include 15 who have not received any dose of a SARS-CoV-2 vaccine and 2 who
 362 receive only the first dose of a two-dose SARS-CoV-2 vaccine series.


363 †P-values correspond to results of Fisher's exact tests.

364 ‡Overweight was defined as a body mass index (BMI) >25 kg/m² but <30 kg/m²; obesity was defined as BMI ≥30
 365 kg/m² but <40 kg/m²; severe obesity was defined as BMI ≥40 kg/m².

366 §The COVID-19 case definition of the Council of State and Territorial Epidemiologists (CSTE) includes fever, chills,
 367 muscle aches, headache, sore throat, nausea/vomiting, diarrhea, fatigue, stuffy/runny nose, cough, shortness of
 368 breath, or loss of taste or smell. [CSTE 2021]

369 ¶ 8 participants (5 fully vaccinated and 3 not fully vaccinated) declined to report symptoms in addition to 15 (14
 370 and 1, respectively) who reported that they had no symptoms


371 **Figure 1. Timelines and results of nasal mid-turbinate specimens collected from enrolled participants,**
372 **Federal prison, Texas, July 12—August 9, 2021**



373


374 The timelines of specimen collection and laboratory results for 95 included participants are represented
375 diagrammatically, indexed by the day of onset. Onset was determined to be either a) date of first onset of self-
376 reported symptom(s) meeting the case definition of COVID-19 or b) date of first positive diagnostic SARS-CoV-2
377 test, whichever occurred first. Each participant is represented by a horizontal line corresponding to the
378 investigation sampling period during their time-course of illness. Participants who were not fully vaccinated
379 (including 2 participants who received only the first dose of a two-dose COVID-19 vaccine series) are depicted at
380 the top of the figure, while fully vaccinated participants are depicted at the bottom. RT-PCR results are
381 represented by solid circles (positive results) or open circles (negative results). For specimens with positive RT-PCR
382 results for which viral culture was performed, culture results are indicated by overlaid blue boxes (positive culture
383 results) or red boxes (negative culture results). Specimens with positive RT-PCR results with a cycle threshold (Ct)
384 value greater than 35 for which viral culture was not performed are indicated by overlaid orange boxes (indicated
385 a presumptive negative viral culture result). Some participants provided specimens during case-finding testing
386 while in quarantine and may have RT-PCR negative specimens collected prior to onset.

387 **Figure 2. SARS-CoV-2 RT-PCR test positivity survival curves for enrolled participants, Federal prison,**
388 **Texas, July 12—August 9, 2021**



389
390 Panels illustrate the results of Turnbull estimation survival functions with a primary endpoint of last positive
391 reverse transcription-polymerase chain reaction (RT-PCR) test result. Solid lines indicate nonparametric maximum
392 likelihood estimates and shaded regions correspond to 95% confidence intervals estimated through modified
393 bootstrap. Survival functions are plotted by Turnbull interval midpoints. Onset was determined to be either a) date
394 of first onset of self-reported symptom(s) meeting the case definition of COVID-19 or b) date of first positive
395 diagnostic SARS-CoV-2 test, whichever occurred first. Panel A depicts RT-PCR positivity by vaccination status (not
396 fully vaccinated participants include 2 participants who received only the first dose of a two-dose COVID-19
397 vaccine series). Panel B depicts positivity by vaccine product among fully vaccinated participants. Panel C depicts
398 positivity according to the time from completion of a COVID-19 vaccine/series to onset. Panel D depicts positivity
399 according to history of known prior SARS-CoV-2 infection.


400 **Figure 3. RT-PCR Cycle Threshold distributions for enrolled participants with confirmed SARS-CoV-2**
401 **infection, Federal prison, Texas, July 12—August 9, 2021**



402


403 Panels illustrate daily medians and interquartile ranges (IQRs) for reverse transcription-polymerase chain reaction
404 (RT-PCR) cycle threshold (Ct) values among specimens with positive RT-PCR results. Solid lines indicate median Ct
405 values and shaded regions indicate IQRs. Percentages at the top of each panel indicate the proportion of
406 specimens with negative RT-PCR results each day Onset was determined to be either a) date of first onset of self-
407 reported symptom(s) meeting the case definition of COVID-19 or b) date of first positive diagnostic SARS-CoV-2
408 test, whichever occurred first. Panel A depicts RT-PCR positivity by vaccination status (not fully vaccinated
409 participants include 2 participants who received only the first dose of a two-dose COVID-19 vaccine series). Panel B
410 depicts positivity by vaccine product among fully vaccinated participants. Panel C depicts positivity according to
411 the time from completion of a COVID-19 vaccine/series to onset. Panel D depicts positivity according to history of
412 known prior SARS-CoV-2 infection.

413 **Figure 4. SARS-CoV-2 viral culture test positivity survival curves for enrolled participants, Federal**
414 **prison, Texas, July 12—August 9, 2021**



415
416 Panels illustrate the results of Turnbull estimation survival functions with a primary endpoint of last positive viral
417 culture test result. Specimens were included as presumptive negative results if no culture was performed but were
418 accompanied by negative RT-PCR results or positive RT-PCR results with Ct>35. Solid lines indicate nonparametric
419 maximum likelihood estimates and shaded regions correspond to 95% confidence intervals estimated through
420 modified bootstrap. Survival functions are plotted by Turnbull interval midpoints. When Turnbull intervals are
421 bounded by positive infinity (resulting from right-censoring in subgroups), survival functions are truncated by open
422 points at the rightmost non-infinite intervals. Onset was determined to be either a) date of first onset of self-
423 reported symptom(s) meeting the case definition of COVID-19 or b) date of first positive diagnostic SARS-CoV-2
424 test, whichever occurred first. Panel A depicts RT-PCR positivity by vaccination status (not fully vaccinated
425 participants include 2 participants who received only the first dose of a two-dose COVID-19 vaccine series). Panel B
426 depicts positivity by vaccine product among fully vaccinated participants. Panel C depicts positivity according to
427 the time from completion of a COVID-19 vaccine/series to onset. Panel D depicts positivity according to history of
428 known prior SARS-CoV-2 infection.

429 **Figure 5. SARS-CoV-2 RT-PCR test positivity (A) and viral culture test positivity (B) stratified by**
 430 **vaccination status and prior infection status for enrolled participants, Federal prison, Texas, July 12—**
 431 **August 9, 2021**



432

433 Panels illustrate the proportions of specimens for which RT-PCR test results (panel A) or viral culture test results
 434 (panel B) were positive, stratified by both vaccination status and history of prior SARS-CoV-2 infection. Solid bars
 435 indicate results for participants with no known prior infections, and striped bars indicate results for participants
 436 with documented prior infections. Specimens were included as presumptive negative results if no culture was
 437 performed but were accompanied by negative RT-PCR results or positive RT-PCR results with Ct>35. Onset was
 438 determined to be either a) date of first onset of self-reported symptom(s) meeting the case definition of COVID-19
 439 or b) date of first positive diagnostic SARS-CoV-2 test, whichever occurred first. Results are depicted only for days
 440 0, 3, 5, 7, and 9 since onset, representing days for which 100% of eligible specimens had viral culture performed.
 441 Bar labels indicate the number of specimens collected from participants in each group for each day. P-values are
 442 reported at the top of each daily grouping and correspond to Fisher's exact test of proportions across the four
 443 groups.

444 **References**

- 445 1. Mancuso M, Eikenberry SE, Gumel AB. Will vaccine-derived protective immunity curtail COVID-
446 19 variants in the US? *Infect Dis Model.* 2021; 6: 1110-34. 10.1016/j.idm.2021.08.008.
- 447 2. Riemersma KK, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian A, et al. Shedding
448 of Infectious SARS-CoV-2 Despite Vaccination. *medRxiv.* 2021: 2021.07.31.21261387.
449 10.1101/2021.07.31.21261387.
- 450 3. Shamier MC, Tostmann A, Bogers S, de Wilde J, Ijpelaar J, van der Kleij WA, et al. Virological
451 characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers. *medRxiv.*
452 2021: 2021.08.20.21262158. 10.1101/2021.08.20.21262158.
- 453 4. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2
454 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public
455 Gatherings - Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep.*
456 2021; 70(31): 1059-62. 10.15585/mmwr.mm7031e2.
- 457 5. Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA. US Department of
458 Health and Human Services. Accessed October 16, 2021. [Available from:
459 https://covid.cdc.gov/covid-data-tracker/#trends_dailycases.
- 460 6. Hagan LM, McCormick DW, Lee C, Sleweon S, Nicolae L, Dixon T, et al. Outbreak of SARS-CoV-2
461 B.1.617.2 (Delta) Variant Infections Among Incarcerated Persons in a Federal Prison - Texas, July-
462 August 2021. *MMWR Morb Mortal Wkly Rep.* 2021; 70(38): 1349-54.
463 10.15585/mmwr.mm7038e3.
- 464 7. Hagan LM, Williams SP, Spaulding AC, Toblin RL, Figlenski J, Ocampo J, et al. Mass Testing for
465 SARS-CoV-2 in 16 Prisons and Jails - Six Jurisdictions, United States, April-May 2020. *MMWR*
466 *Morb Mortal Wkly Rep.* 2020; 69(33): 1139-43. 10.15585/mmwr.mm6933a3.

- 467 8. Maruschak L, Bronson J, Alper M. Medical problems reported by prisoners, survey of prison
468 inmates, 2016. Washington, DC. US Department of Justice, Bureau of Justice Statistics. 2021.
469 Available from:
470 <https://bjs.ojp.gov/sites/g/files/xyckuh236/files/media/document/mprpspi16st.pdf>.
- 471 9. McMichael TM, Clark S, Pogojans S, Kay M, Lewis J, Baer A, et al. COVID-19 in a Long-Term Care
472 Facility - King County, Washington, February 27-March 9, 2020. *MMWR Morb Mortal Wkly Rep*.
473 2020; 69(12): 339-42. 10.15585/mmwr.mm6912e1.
- 474 10. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, et al. Severe Acute Respiratory
475 Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. *Emerg Infect Dis*.
476 2020; 26(6): 1266-73. 10.3201/eid2606.200516.
- 477 11. Council of State and Territorial Epidemiologists. Update to the standardized surveillance case
478 definition and national notification for 2019 novel coronavirus disease (COVID-19). Accessed
479 October 15, 2021. [Available from: [https://cdn.ymaws.com/www.cste.org/resource/resmgr/21-](https://cdn.ymaws.com/www.cste.org/resource/resmgr/21-ID-01_COVID-19_updated_Au.pdf)
480 [ID-01_COVID-19_updated_Au.pdf](https://cdn.ymaws.com/www.cste.org/resource/resmgr/21-ID-01_COVID-19_updated_Au.pdf).
- 481 12. Fay MP, Shaw PA. Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The
482 interval R package. *J Stat Softw*. 2010; 36(2). 10.18637/jss.v036.i02.
- 483 13. Ke R, Martinez PP, Smith RL, Gibson LL, Achenbach CJ, McFall S, et al. Longitudinal analysis of
484 SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and
485 restricted tissue distribution. *medRxiv*. 2021. 10.1101/2021.08.30.21262701.
- 486 14. Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily sampling of early SARS-
487 CoV-2 infection reveals substantial heterogeneity in infectiousness. *medRxiv*. 2021.
488 10.1101/2021.07.12.21260208.
- 489 15. Griffin JB, Haddix M, Danza P, Fisher R, Koo TH, Traub E, et al. SARS-CoV-2 Infections and
490 Hospitalizations Among Persons Aged ≥ 16 Years, by Vaccination Status - Los Angeles County,

- 491 California, May 1-July 25, 2021. *MMWR Morb Mortal Wkly Rep.* 2021; 70(34): 1170-6.
492 10.15585/mmwr.mm7034e5.
- 493 16. Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston D, Li M, et al. Infection with the SARS-
494 CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha
495 Variant in both Unvaccinated and Vaccinated Individuals. *medRxiv.* 2021.
496 10.1101/2021.08.15.21262077.
- 497 17. Christensen PA, Olsen RJ, Long SW, Subedi S, Davis JJ, Hodjat P, et al. Delta variants of SARS-CoV-
498 2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas.
499 *medRxiv.* 2021: 2021.07.19.21260808. 10.1101/2021.07.19.21260808.
- 500 18. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of SARS-CoV-2
501 vaccination on Alpha & Delta variant transmission. *medRxiv.* 2021: 2021.09.28.21264260.
502 10.1101/2021.09.28.21264260.
- 503 19. Chia PY, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, et al. Virological and
504 serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center
505 cohort study. *medRxiv.* 2021: 2021.07.28.21261295. 10.1101/2021.07.28.21261295.
- 506 20. Singanayagam A, Hakki S, Dunning J, Madon KJ, Crone M, Koycheva A, et al. Community
507 transmission and viral load kinetics of SARS-CoV-2 Delta (B.1.617.2) variant in vaccinated and
508 unvaccinated individuals. *Preprint Available at SSRN: <https://ssrncom/abstract=3918287> or*
509 *<http://dxdoiorq/102139/ssrn3918287>.* 2021.
- 510 21. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, et al. Effect of Delta
511 variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK.
512 *Nat Med.* 2021. 10.1038/s41591-021-01548-7.

- 513 22. Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of SARS-
514 CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. *Clin Infect*
515 *Dis.* 2021. 10.1093/cid/ciab687.
- 516 23. Ford L, Lee C, Pray IW, Cole D, Bigouette JP, Abedi GR, et al. Epidemiologic Characteristics
517 Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen-Based
518 Test Results, Real-Time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) Cycle
519 Threshold Values, Subgenomic RNA, and Viral Culture Results From University Testing. *Clin Infect*
520 *Dis.* 2021; 73(6): e1348-e55. 10.1093/cid/ciab303.
- 521 24. Centers for Disease Control and Prevention. Interim guidance on management of coronavirus
522 disease 2019 (COVID-19) in correctional and detention facilities. Atlanta, GA. US Department of
523 Health and Human Services. Accessed October 29, 2021. [Available from:
524 [https://www.cdc.gov/coronavirus/2019-ncov/community/correction-detention/guidance-](https://www.cdc.gov/coronavirus/2019-ncov/community/correction-detention/guidance-correctional-detention.html)
525 [correctional-detention.html](https://www.cdc.gov/coronavirus/2019-ncov/community/correction-detention/guidance-correctional-detention.html).
526